Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CubeSmart (CUBE) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance

IDEXX Laboratories, Inc.Trade

Price performance (Past 24H)

Key statistics

CubeSmart vs IDEXX Laboratories, Inc. — how do they compare? CubeSmart trades at $37.56 (market cap $8.45B), while IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is far larger — about 4.8× CubeSmart's market cap, and CubeSmart pays a 5.65% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold CubeSmart for 89 Days and IDEXX Laboratories, Inc. for 46 Days on average.

CUBEIDXX
Market Cap
$8.45B$40.43B
Volume
2,879,532692,164
Sector
Real EstateHealth
52-Week High
$42.50$766.68
52-Week Low
$35.36$504.70
Typical Hold Time
89 Days46 Days
Enterprise Value
$11.97B$41.32B
Dividend Yield
5.65%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CubeSmart

CubeSmart (CUBE) trades at $37.23, down 1.4% on the day, amid a bearish technical signal from moving averages. The self-storage REIT reported mixed Q2 2026 results with an FFO miss but revenue beat, and same-store NOI declined 0.7%. Financials show strong gross margins of 67.83% and net income margin of 29.41%, though net income has trended down from $411M in 2023 to $334M in 2025. Analyst consensus is a Buy with a $44.00 price target, implying 18% upside, but technical indicators suggest near-term resistance at $38.

CUBE offers a 5.4% dividend yield with a payout scheduled for October 2026, supporting income-focused investors. Upside is driven by moderating supply and strengthening demand in the self-storage sector, but risks include high leverage with $2.99B long-term debt and macroeconomic sensitivity. Institutional activity is mixed, with new positions from Deutsche Bank and Barrow Hanley offset by selling from HSBC. The stock presents a value opportunity if operational improvements materialize, though debt levels and same-store performance warrant caution.

IDEXX Laboratories, Inc.

IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.

The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CUBE
97% Buy3% Sell
Avg holding period · 89 Days
IDXX

No sentiment data available yet.

About CubeSmart

CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Most of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. CubeSmart derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.

Read more on CUBE →

About IDEXX Laboratories, Inc.

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.

Read more on IDXX →